Browsing Tag
ensifentrine
2 posts
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.